Neurontin Ruling Would Kill Off-Label Use, 1st Circ. Hears

Law360, New York (August 8, 2012, 3:22 PM EDT) -- A pharmaceutical industry group on Tuesday backed Pfizer Inc.’s challenge of a $142 million jury award in multidistrict litigation over off-label marketing of painkiller Neurontin, telling the First Circuit that the verdict could stifle acceptable off-label drug uses and chill scientific discussion.

In the lower court, U.S. District Judge Patti B. Saris found that it is a material misrepresentation to claim a drug is effective for an off-label use unless the supporting evidence meets the U.S. Food and Drug Administration’s regulatory standard for drug approval, according...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.